New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export PFE’s income statement to Excel — free account
Pfizer Inc.
PFEHealthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −9.68%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
27.71
0.14
+0.51%
Follow PFE
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
Of every $100 of revenue, $19.61 was left as profit. What is an income statement?
| Revenue | 16.6 | 100.0% |
|---|---|---|
| Cost of revenue | −4.0 | −24.3% |
| Gross profit | 12.6 | 75.7% |
| Research & development | −3.0 | −18.2% |
| Selling, general & admin | −3.3 | −19.8% |
| Other operating costs | −2.6 | −15.6% |
| Operating income | 3.7 | 22.1% |
| Other income, net | −0.3 | −1.7% |
| Income tax | −0.1 | −0.8% |
| Net income | 3.3 | 19.6% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $17.6B | $14.5B | $15.0B | $16.6B |
| Operating income | $2.9B | $4.0B | $3.1B | $3.7B |
| Net income | −$1.6B | $2.7B | −$238M | $3.3B |
| Net margin (right axis) | −9.3% | 18.7% | −1.6% | 19.6% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
16,583.00 | 15,034.00 | 14,451.00 | 17,557.00 |
+8 more quarters Free account |
Revenue Growth |
(0.43%) | 2.60% | 5.37% | (1.16%) | |
Cost of Revenue |
4,028.00 | 4,092.00 | 3,548.00 | 5,272.00 | |
Gross Profit |
12,555.00 | 10,942.00 | 10,903.00 | 12,285.00 | |
R&D Expenses |
3,016.00 | 2,809.00 | 2,490.00 | 3,206.00 | |
SG&A Expenses |
3,279.00 | 3,411.00 | 2,961.00 | 4,162.00 | |
Operating Income |
3,672.00 | 3,064.00 | 4,032.00 | 2,872.00 | |
Non-operating Income/Expense |
(288.00) | (3,716.00) | (861.00) | (4,515.00) | |
| 3,385.00 | (653.00) | 3,170.00 | (1,643.00) | ||
Income Tax Provision |
134.00 | (407.00) | 461.00 | (2.00) | |
Income after Tax |
3,251.00 | (246.00) | 2,709.00 | (1,641.00) | |
Dividends (Preferred) |
— | 1.00 | 1.00 | — | |
Non-Controlling Interest |
10.00 | 10.00 | 8.00 | 8.00 | |
Net Income Common |
3,242.00 | (248.00) | 2,687.00 | (1,647.00) | |
EPS (Basic) |
0.57 | (0.04) | 0.47 | (0.29) | |
EPS (Diluted) |
0.56 | (0.04) | 0.47 | (0.29) | |
Shares (Basic, Weighted) |
5,700.00 | 5,699.00 | 5,691.00 | 5,683.00 | |
Shares (Diluted, Weighted) |
5,751.00 | 5,699.00 | 5,731.00 | 5,713.00 | |
Gross Margin |
75.71% | 72.78% | 75.45% | 69.97% | |
EBIT Margin |
22.14% | 20.38% | 27.90% | 16.36% | |
EBT margin |
20.41% | (4.34%) | 21.94% | (9.36%) | |
Net Profit Margin |
19.55% | (1.65%) | 18.59% | (9.38%) | |
EBITDA |
5,249.00 | 4,686.00 | 5,645.00 | 4,559.00 | |
EBIT |
3,672.00 | 3,064.00 | 4,032.00 | 2,872.00 | |
Income from Continuous Operations |
3,251.00 | (246.00) | 2,709.00 | (1,639.00) | |
Income from Discontinued Operations |
0.00 | 8.00 | (13.00) | — | |
Consolidated Net Income/Loss |
3,252.00 | (237.00) | 2,696.00 | (1,639.00) | |
EPS (Basic, from Continuous Ops) |
0.57 | (0.04) | 0.48 | (0.28) | |
EPS (Diluted, from Cont. Ops) |
0.56 | (0.04) | 0.47 | (0.29) | |
EPS (Diluted, from Disc. Ops) |
0.00 | 0.00 | 0.00 | — | |
EPS (Basic, from Discontinued Ops) |
0.00 | 0.00 | 0.00 | — | |
EPS (Basic, Consolidated) |
0.57 | (0.04) | 0.47 | (0.29) | |
EPS (Diluted, Consolidated) |
0.57 | (0.04) | 0.47 | (0.29) | |
Shares (Diluted, Average) |
5,751.00 | 5,699.00 | 5,731.00 | 5,686.00 | |
EBITDA Margin |
31.65% | 31.17% | 39.06% | 25.97% | |
Operating Cash Flow Margin |
32.41% | 5.55% | 18.10% | 30.46% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026